Tempus ECG-Low EF vs Study Watch
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary need is to quickly screen for signs of low left ventricular ejection fraction (LVEF ≤40%) in patients aged 40 or older using a standard 12-lead ECG within a clinical diagnostic workflow. This tool is ideal for aiding clinicians in identifying patients at risk of heart failure who may require further, more definitive evaluation.
View Tempus ECG-Low EF →Choose Study Watch if…
Choose Verily Study Watch if your objective is continuous, non-invasive physiological monitoring for clinical research studies, requiring long-term data collection of parameters like ECG, heart rate, and movement. This device is best suited for researchers needing to gather extensive, real-world physiological data over time for analysis within a cloud-based platform.
View Study Watch →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | Study Watch |
|---|---|---|
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | The Study Watch is a wrist-worn, multi-sensor wearable device used for data collection in clinical trials. Data from the watch is encrypted and sent securely to the Verily Cloud using a USB syncing and charging cradle and a wireless connectivity bridge (Verily Study Hub). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-Low EFTempus ECG-Low EF integrates directly into existing clinical diagnostic workflows by analyzing standard 12-lead ECGs, providing a straightforward binary output for clinicians. In contrast, Verily Study Watch requires patient wearability and data upload to a cloud platform, which introduces additional steps and potential adherence challenges for patients and a separate interface for clinicians.
Clinical Value
Tempus ECG-Low EFTempus ECG-Low EF offers direct clinical value by providing an FDA-cleared AI-powered diagnostic aid for detecting signs of low LVEF from standard ECGs, directly assisting clinicians in identifying patients at risk of heart failure. Verily Study Watch, while FDA-cleared for continuous monitoring and irregular pulse detection, is primarily positioned for clinical research and data collection, offering more indirect or long-term clinical insights rather than immediate diagnostic support for a specific condition like low LVEF.
Pricing & Value
TieBoth tools have non-public pricing, making a direct comparison of their cost-effectiveness and value proposition challenging without specific financial details. While Tempus ECG-Low EF offers a direct diagnostic aid that could potentially optimize clinical pathways, Verily Study Watch provides value through continuous data collection for research and long-term monitoring, serving different but equally important needs in healthcare.
Enterprise Readiness
Tempus ECG-Low EFTempus ECG-Low EF demonstrates strong enterprise readiness with FDA clearance, HIPAA compliance, and explicit BAA, alongside its integration into existing healthcare workflows. While Verily Study Watch also has FDA clearance and claims compliance, the mention of an ongoing lawsuit alleging BAA and HIPAA breaches, even if denied, introduces a significant risk factor for enterprise adoption.
Innovation
TieBoth tools showcase significant innovation in their respective domains. Tempus ECG-Low EF innovates by applying AI to standard ECGs to detect a complex condition like low LVEF, enhancing existing diagnostic capabilities. Verily Study Watch innovates through its multi-sensor wearable for continuous physiological monitoring and cloud-based AI analysis, opening new avenues for remote data collection and research.
Support & Docs
TieBoth Tempus and Verily, as established companies in the healthcare AI space, appear to offer robust support and documentation. Tempus provides direct contact channels and emphasizes customer service, with evidence of FAQs and support for its products. Verily offers a dedicated support portal with product documentation, regulatory information, and various contact options for its different solutions, including the Study Watch. Neither tool's documentation or support appears significantly superior to the other based on available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | Study Watch |
|---|---|---|
| Product Name | Tempus ECG-Low EF | Study Watch |
| Primary Purpose/Description | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. | Prescription-only, sensor-based wearable device for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform. |
| Company | Tempus AI | Verily Life Sciences |
| Key Data Analyzed/Collected | 12-lead ECG recordings | ECG, heart rate, electrodermal activity, inertial movements |
| Output/Monitoring Type | Binary output (Low LVEF Detected / Not Detected) | Continuous physiological monitoring, On-demand single-channel ECG, Irregular pulse monitor |
| Target Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Neurology, Sleep Medicine |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and Study Watch.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or Study Watch
Backers
Who funded each tool's parent company.